Ken Griffin Dynavax Technologies Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$10.05 - $11.61 $311,550 - $359,910	31,000 Added 33.26%	124,200 $1.38 Million
Q2 2024 Aug 14, 2024	BUY	$10.73 - $12.58 $361,601 - $423,946	33,700 Added 56.64%	93,200 $1.05 Million
Q1 2024 May 15, 2024	SELL	$11.7 - $14.98 $85,410 - $109,354	-7,300 Reduced 10.93%	59,500 $738,000
Q4 2023 Feb 14, 2024	SELL	$13.09 - $14.98 $113,883 - $130,326	-8,700 Reduced 11.52%	66,800 $933,000
Q3 2023 Nov 14, 2023	SELL	$12.64 - $14.99 $291,984 - $346,269	-23,100 Reduced 23.43%	75,500 $1.12 Million
Q2 2023 Aug 14, 2023	BUY	$9.85 - $13.17 $220,640 - $295,008	22,400 Added 29.4%	98,600 $1.27 Million
Q1 2023 May 15, 2023	BUY	$9.44 - $11.88 $55,696 - $70,092	5,900 Added 8.39%	76,200 $747,000
Q4 2022 Feb 14, 2023	SELL	$10.27 - $13.29 $192,049 - $248,522	-18,700 Reduced 21.01%	70,300 $747,000
Q3 2022 Nov 14, 2022	SELL	$9.93 - $17.44 $439,899 - $772,592	-44,300 Reduced 33.23%	89,000 $929,000

273

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.54B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.